Provided by Tiger Trade Technology Pte. Ltd.

Cardiff Oncology, Inc.

1.60
+0.12008.11%
Post-market: 1.58-0.0200-1.25%19:50 EST
Volume:927.42K
Turnover:1.46M
Market Cap:107.78M
PE:-2.02
High:1.62
Open:1.51
Low:1.50
Close:1.48
52wk High:4.99
52wk Low:1.48
Shares:67.36M
Float Shares:65.73M
Volume Ratio:0.66
T/O Rate:1.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7940
EPS(LYR):-0.9539
ROE:-102.71%
ROA:-52.99%
PB:2.21
PE(LYR):-1.68

Loading ...

Company Profile

Company Name:
Cardiff Oncology, Inc.
Exchange:
NASDAQ
Establishment Date:
1999
Employees:
33
Office Location:
11055 Flintkote Avenue,San Diego,California,United States
Zip Code:
92121
Fax:
- -
Introduction:
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Directors

Name
Position
Rodney S. Markin
Chairman of the Board
Gary W. Pace
Independent Director
James O. Armitage
Independent Director
Lale White
Independent Director
Mani Mohindru
Independent Director and Interim CEO
Renee P. Tannenbaum
Independent Director

Shareholders

Name
Position
Brigitte Lindsay
Chief Accounting Officer
Mani Mohindru
Independent Director and Interim CEO
Tod Smeal
Chief Scientific Officer